Pharmaceutics (Nov 2021)

Modulating the Blood–Brain Barrier: A Comprehensive Review

  • Rory Whelan,
  • Grainne C. Hargaden,
  • Andrew J. S. Knox

DOI
https://doi.org/10.3390/pharmaceutics13111980
Journal volume & issue
Vol. 13, no. 11
p. 1980

Abstract

Read online

The highly secure blood–brain barrier (BBB) restricts drug access to the brain, limiting the molecular toolkit for treating central nervous system (CNS) diseases to small, lipophilic drugs. Development of a safe and effective BBB modulator would revolutionise the treatment of CNS diseases and future drug development in the area. Naturally, the field has garnered a great deal of attention, leading to a vast and diverse range of BBB modulators. In this review, we summarise and compare the various classes of BBB modulators developed over the last five decades—their recent advancements, advantages and disadvantages, while providing some insight into their future as BBB modulators.

Keywords